$INBP
INTEGRATED BIOPHARMA INC

2021 Form 10-K Financial Statement

#000143774921021375 Filed on September 02, 2021

View on sec.gov

Income Statement

Concept 2021 2020 Q2 2020
Revenue $63.56M $13.54M $52.77M
YoY Change 20.45% -0.36% 5.59%
Cost Of Revenue $54.08M $12.09M $46.04M
YoY Change 17.46% 0.67% 5.23%
Gross Profit $9.480M $1.450M $6.727M
YoY Change 40.92% -8.17% 8.12%
Gross Profit Margin 14.92% 10.71% 12.75%
Selling, General & Admin $3.696M $832.0K $3.468M
YoY Change 6.57% -17.21% -1.42%
% of Gross Profit 38.99% 57.38% 51.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $337.0K $73.00K $312.0K
YoY Change 8.01% -16.09% -2.8%
% of Gross Profit 3.55% 5.03% 4.64%
Operating Expenses $3.696M $832.0K $3.468M
YoY Change 6.57% -17.21% -1.42%
Operating Profit $5.784M $618.0K $3.259M
YoY Change 77.48% 7.67% 20.53%
Interest Expense $256.0K $23.00K $397.0K
YoY Change -35.52% -134.33% -36.98%
% of Operating Profit 4.43% 3.72% 12.18%
Other Income/Expense, Net $1.463M $24.00K -$171.0K
YoY Change -955.56% -148.0% -74.17%
Pretax Income $7.247M $665.0K $3.088M
YoY Change 134.68% 45.51% 51.22%
Income Tax -$766.0K -$1.236M -$1.020M
% Of Pretax Income -10.57% -185.86% -33.03%
Net Earnings $8.013M $1.901M $4.108M
YoY Change 95.06% 428.06% 143.36%
Net Earnings / Revenue 12.61% 14.05% 7.78%
Basic Earnings Per Share $0.27 $0.14
Diluted Earnings Per Share $0.25 $58.33K $0.13
COMMON SHARES
Basic Shares Outstanding 29.70M 29.57M 29.57M
Diluted Shares Outstanding 32.11M 31.16M

Balance Sheet

Concept 2021 2020 Q2 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.0K $402.0K $402.0K
YoY Change -47.76% -15.37% -15.37%
Cash & Equivalents $402.0K
Short-Term Investments
Other Short-Term Assets $317.0K $451.0K $451.0K
YoY Change -29.71% 30.35% 30.35%
Inventory $11.70M $11.70M $10.10M
Prepaid Expenses
Receivables $5.776M $5.507M $5.507M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.00M $16.46M $16.46M
YoY Change 9.34% 16.92% 16.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.107M $1.742M $4.520M
YoY Change -9.14% -2.02% -10.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.335M $1.963M $1.963M
YoY Change 69.89% 202.47% 202.47%
Total Long-Term Assets $7.442M $6.483M $6.483M
YoY Change 14.79% 13.52% 13.52%
TOTAL ASSETS
Total Short-Term Assets $18.00M $16.46M $16.46M
Total Long-Term Assets $7.442M $6.483M $6.483M
Total Assets $25.44M $22.94M $22.94M
YoY Change 10.88% 15.94% 15.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.496M $4.358M $4.358M
YoY Change -19.78% 13.05% 13.05%
Accrued Expenses $2.110M $1.872M $1.872M
YoY Change 12.71% 15.77% 15.77%
Deferred Revenue
YoY Change
Short-Term Debt $2.173M $4.046M $4.046M
YoY Change -46.29% -30.65% -30.65%
Long-Term Debt Due $1.457M $2.823M $2.823M
YoY Change -48.39% 169.63% 169.63%
Total Short-Term Liabilities $9.236M $13.10M $13.10M
YoY Change -29.49% 6.04% 6.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.436M $1.436M
YoY Change -100.0% -47.24% -47.24%
Other Long-Term Liabilities $1.870M $2.342M $2.342M
YoY Change -20.15% -17.01% -17.01%
Total Long-Term Liabilities $1.870M $1.436M $3.778M
YoY Change -50.5% -47.24% -31.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.236M $13.10M $13.10M
Total Long-Term Liabilities $1.870M $1.436M $3.778M
Total Liabilities $11.11M $16.88M $16.88M
YoY Change -34.19% -5.7% -5.7%
SHAREHOLDERS EQUITY
Retained Earnings -$44.16M
YoY Change -8.51%
Common Stock $59.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $99.00K
YoY Change 0.0%
Treasury Stock Shares $34.90K
Shareholders Equity $14.33M $6.067M $6.067M
YoY Change
Total Liabilities & Shareholders Equity $25.44M $22.94M $22.94M
YoY Change 10.88% 15.94% 15.94%

Cashflow Statement

Concept 2021 2020 Q2 2020
OPERATING ACTIVITIES
Net Income $8.013M $1.901M $4.108M
YoY Change 95.06% 428.06% 143.36%
Depreciation, Depletion And Amortization $337.0K $73.00K $312.0K
YoY Change 8.01% -16.09% -2.8%
Cash From Operating Activities $3.050M -$2.210M $1.339M
YoY Change 127.78% -452.47% 308.23%
INVESTING ACTIVITIES
Capital Expenditures $295.0K -$56.00K $214.0K
YoY Change 37.85% -12.5% -48.31%
Acquisitions
YoY Change
Other Investing Activities $96.00K $16.00K $104.0K
YoY Change -7.69% -1400.0%
Cash From Investing Activities -$199.0K -$40.00K -$110.0K
YoY Change 80.91% -37.5% -73.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.043M 2.087M -1.302M
YoY Change 133.72% -502.12% -481.82%
NET CHANGE
Cash From Operating Activities 3.050M -2.210M 1.339M
Cash From Investing Activities -199.0K -40.00K -110.0K
Cash From Financing Activities -3.043M 2.087M -1.302M
Net Change In Cash -192.0K -163.0K -73.00K
YoY Change 163.01% -470.45% -129.55%
FREE CASH FLOW
Cash From Operating Activities $3.050M -$2.210M $1.339M
Capital Expenditures $295.0K -$56.00K $214.0K
Free Cash Flow $2.755M -$2.154M $1.125M
YoY Change 144.89% -411.72% -1408.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001016504
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29820277
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 dei Entity Public Float
EntityPublicFloat
6839052
CY2021 dei Entity Registrant Name
EntityRegistrantName
INTEGRATED BIOPHARMA INC
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Security12g Title
Security12gTitle
Common Stock, $.002 par value per share
CY2021Q2 inbp Cost Method Investment Ownership Percentage
CostMethodInvestmentOwnershipPercentage
0.06
CY2021 inbp Effective Income Tax Rate Reconciliation Other State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationOtherStateAndLocalIncomeTaxes
0.025
CY2020 inbp Effective Income Tax Rate Reconciliation Other State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationOtherStateAndLocalIncomeTaxes
0.025
CY2021 inbp Effective Income Tax Rate Reconciliation Ppp Loan Forgiveness
EffectiveIncomeTaxRateReconciliationPppLoanForgiveness
-0.074
CY2020 inbp Effective Income Tax Rate Reconciliation Ppp Loan Forgiveness
EffectiveIncomeTaxRateReconciliationPppLoanForgiveness
CY2021 inbp Finance Lease Expense
FinanceLeaseExpense
26000
CY2020 inbp Finance Lease Expense
FinanceLeaseExpense
70000
CY2021 inbp Gains Losses On Extinguishment Of Debt Including Interest
GainsLossesOnExtinguishmentOfDebtIncludingInterest
1659000
CY2020 inbp Gains Losses On Extinguishment Of Debt Including Interest
GainsLossesOnExtinguishmentOfDebtIncludingInterest
CY2021 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-490000
CY2020 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-462000
CY2021Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
2586000
CY2020Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
3141000
CY2021 inbp Operating Lease Interest Expense
OperatingLeaseInterestExpense
2000
CY2020 inbp Operating Lease Interest Expense
OperatingLeaseInterestExpense
13000
CY2021 inbp Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
489000
CY2020 inbp Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
460000
CY2021 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
75000
CY2020 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
194000
CY2021 inbp Trade In Value On Likekind Exchanges
TradeInValueOnLikekindExchanges
23000
CY2020 inbp Trade In Value On Likekind Exchanges
TradeInValueOnLikekindExchanges
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3496000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4358000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5776000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5507000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1610000
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1384000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7294000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7312000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50516000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50263000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
59000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
231000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
231000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
53000
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
99000
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2562000
CY2021Q2 us-gaap Assets
Assets
25440000
CY2020Q2 us-gaap Assets
Assets
22944000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
17998000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
16461000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
91000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
210000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
402000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
475000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-192000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73000
CY2021Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29838177
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29680843
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29803277
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29645943
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
60000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
59000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
54079000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
46042000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-40000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
619000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
369000
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
1190000
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
549000
CY2021Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
9000
CY2020Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
39000
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3268000
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1883000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1385000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1349000
CY2021Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
299000
CY2020Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
258000
CY2021Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
195000
CY2020Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
34000
CY2021Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
128000
CY2020Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
142000
CY2021Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
186000
CY2020Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
254000
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
3268000
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
1883000
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5691000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7047000
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3073000
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5648000
CY2021Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
158000
CY2020Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
204000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
73000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
68000
CY2021Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
67000
CY2020Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
80000
CY2021 us-gaap Depreciation
Depreciation
337000
CY2020 us-gaap Depreciation
Depreciation
312000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
337000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
312000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.106
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.33
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.348
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.69
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.014
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.029
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.095
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.095
CY2021 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000
CY2020 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
13000
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
75000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
24000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
57000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
14000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
4000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1639000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
CY2021 us-gaap Gross Profit
GrossProfit
9480000
CY2020 us-gaap Gross Profit
GrossProfit
6727000
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
7247000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3088000
CY2021Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-766000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1020000
CY2021 us-gaap Income Tax Expense Benefit Continuing Operations Government Grants
IncomeTaxExpenseBenefitContinuingOperationsGovernmentGrants
23000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
558000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
384000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-937000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
487000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
294000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1082000
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
42000
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
22000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-43000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1594000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1282000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
226000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
237000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2414616
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1584995
CY2021 us-gaap Interest Expense
InterestExpense
256000
CY2020 us-gaap Interest Expense
InterestExpense
397000
CY2021 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
2000
CY2020 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
13000
CY2021 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
19000
CY2020 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
CY2021 us-gaap Interest Expense Other
InterestExpenseOther
23000
CY2020 us-gaap Interest Expense Other
InterestExpenseOther
26000
CY2021 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
42000
CY2020 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
22000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
201000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
367000
CY2021Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
14000
CY2020Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
19000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
812000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
879000
CY2021Q2 us-gaap Inventory Net
InventoryNet
11695000
CY2020Q2 us-gaap Inventory Net
InventoryNet
10101000
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7941000
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6610000
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2942000
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2612000
CY2021Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
67000
CY2020Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
134000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2586000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
582000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
316000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
542000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
572000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
574000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
216000
CY2021Q2 us-gaap Liabilities
Liabilities
11106000
CY2020Q2 us-gaap Liabilities
Liabilities
16877000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25440000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22944000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9236000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13099000
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2173000
CY2020Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4046000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
3639000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
8344000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1457000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2823000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1436000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3043000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1302000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-199000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3050000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1339000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
8013000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
4108000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1463000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171000
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
5784000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
3259000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
664000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
670000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2370000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
500000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1870000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2342000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
663000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
657000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2365000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2824000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
317000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
451000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
51000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
295000
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
230000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
295000
CY2021 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt">Reclassifications. </div></div>Certain prior year amounts have been reclassified to conform to the current year presentation.</div>
CY2021 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
57662000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
47213000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1639000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
96000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
101000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9036000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9008000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1742000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1696000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
25000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15000
CY2021 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
56000
CY2020 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
72000
CY2021 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
59535000
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
49001000
CY2021 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
75000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
194000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1118000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
966000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36143000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44156000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
63559000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
52769000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
30000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3696000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3468000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
231000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
59000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7480669
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2875533
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3114099
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.16
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.19
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
36667
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
137500
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3333
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
770000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3761500
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3344000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3916666
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.09
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.15
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.10
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.21
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.14
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.21
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.66
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.09
CY2021 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
0.72
CY2021Q2 us-gaap Share Price
SharePrice
0.65
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2825000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
846000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y255D
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
157334
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
14334000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
6067000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1893000
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2021 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-53000
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
103000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates.</div></div> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. The most significant estimates include:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;sales returns and allowances;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;allowance for doubtful accounts;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;inventory valuation;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;valuation and recoverability of long-lived assets;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;income taxes and valuation allowance on deferred income taxes, and;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">&#x25cf;&nbsp;&nbsp;&nbsp;&nbsp;accruals for, and the probability of, the outcome of current litigation, if any.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.</div></div></div></div>
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2575000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1898000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32113681
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31157250
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29699065
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29572255

Files In Submission

Name View Source Status
0001437749-21-021375-index-headers.html Edgar Link pending
0001437749-21-021375-index.html Edgar Link pending
0001437749-21-021375.txt Edgar Link pending
0001437749-21-021375-xbrl.zip Edgar Link pending
ex_262155.htm Edgar Link pending
ex_262156.htm Edgar Link pending
ex_262157.htm Edgar Link pending
ex_262158.htm Edgar Link pending
ex_262159.htm Edgar Link pending
ex_262160.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inbp-20210630.xml Edgar Link completed
inbp-20210630.xsd Edgar Link pending
inbp-20210630_cal.xml Edgar Link unprocessable
inbp-20210630_def.xml Edgar Link unprocessable
inbp-20210630_lab.xml Edgar Link unprocessable
inbp-20210630_pre.xml Edgar Link unprocessable
inbp20210630_10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending